The field of cancer immunotherapy has been re-energized by the application of chimeric
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …

Chimeric antigen receptor (CAR) T cells are engineered constructs composed of synthetic
receptors that direct T cells to surface antigens for subsequent elimination. Many CAR …

Histone deacetylases (HDAC) are therapeutic targets in multiple cancers. ACY241, an
HDAC6 selective inhibitor, has shown anti-multiple myeloma (MM) activity in combination …

Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy,
yet the frequency of responding patients is limited by inadequate T-cell priming secondary to …

Recent advances in genetic engineering have enabled the delivery of clinical trials using
patient T cells redirected to recognize tumor-associated antigens. The most dramatic results …

Simple Summary Several clinical protocols are exploring the anticancer effect of
immunotherapy combined to targeted therapy. Indeed, emerging evidence demonstrates …

The proline-rich Akt substrate of 40 kDa (PRAS40) is a substrate of Akt and a component of
the mammalian target of rapamycin complex 1 (mTORC1). Locating at the crossroad of the …

A key predictor for the success of gene-modified T cell therapies for cancer is the
persistence of transferred cells in the patient. The propensity of less differentiated memory T …

A significant proportion of hematological malignancies remain limited in treatment options.
Immune system modulation serves as a promising therapeutic approach to eliminate …

Osteosarcoma (OS), which is a common and aggressive primary bone malignancy, occurs
mainly in children and adolescent. Long noncoding RNAs (lncRNAs) are reported to play a …